| Dr Dawn Laporte, MD | |
|
601 N Caroline St, Rm 5210, Baltimore, MD 21287-0006 | |
| (410) 955-3134 | |
| Not Available |
| Full Name | Dr Dawn Laporte |
|---|---|
| Gender | Female |
| Speciality | Orthopedic Surgery |
| Experience | 29 Years |
| Location | 601 N Caroline St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023072238 | NPI | - | NPPES |
| 903A | Other | MD | CAREFIRST MARYLAND |
| DE5302 | Other | MD | RAILROAD MEDICARE |
| DC8030 | Other | MD | RAILROAD MEDICARE |
| J848 | Other | MD | CAREFIRST DC |
| 331950400 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | D0055657 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 4981745098 | 571 |
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer.
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
› Verified 8 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer.
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
› Verified 8 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000347 |
News Archive
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer.
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
› Verified 8 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1922655166 PECOS PAC ID: 4981745098 Enrollment ID: O20191010002241 |
News Archive
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer.
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dawn Laporte, MD Po Box 64664, Baltimore, MD 21264-4664 Ph: () - | Dr Dawn Laporte, MD 601 N Caroline St, Rm 5210, Baltimore, MD 21287-0006 Ph: (410) 955-3134 |
News Archive
Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.
Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer.
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
› Verified 8 days ago
Robert J Brumback, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
Dr. Milford Howarth Marchant Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2900 S Hanover St, Baltimore, MD 21225 Phone: 410-350-8336 Fax: 410-350-7178 | |
Dr. Michelle Ghert, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 110 S Paca St Fl 6, Baltimore, MD 21201 Phone: 614-397-2721 | |
Henry R Boucher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 North Calvert Street, Suite 400, Baltimore, MD 21218 Phone: 410-554-2270 Fax: 410-261-2726 | |
John J Carbone, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3001 S Hanover St, Gruehn Bldg, Ste 502, Baltimore, MD 21225 Phone: 410-350-8300 | |
Paul C Mcafee, M.D., MBA Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3333 N Calvert St Ste 655, Baltimore, MD 21218 Phone: 410-554-2175 Fax: 410-554-2917 |